Menopause can worsen symptoms of bipolar disorder. In rare cases, it may trigger bipolar disorder. Menopause is a factor when ...
Titusville: Johnson & Johnson has announced the decision to discontinue the Phase 3 VENTURA development program evaluating ...
MedPage Today on MSN2d
Chronic Pain Sufferers No Stranger to Depression and AnxietyAmong 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...
TORONTO, ON / ACCESS Newswire / March 5, 2025 / NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI)(OTCQB:AINMF)(Frankfurt:8TV) a generative AI software leader in clinical trial ...
Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...
Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback